IL-12/IL-23 p40 Rat anti-Mouse, Clone: 30517, Invitrogen
Rat Monoclonal Antibody
Manufacturer: Invitrogen MA523723
Polymorphisms exist in the mouse IL-12 p40 sequence. This antibody recognizes an allelic epitope found in the p40 subunit of several mouse strains including BALB/c, C57BL/6, CBA, C3H, DBA/1, NOR, I29/J, and A.SW. This antibody does not recognize the allelic variant that occurs in strains AKR, DBA/2, NOD, NZB, NZC, NZO, NZW, or SJL (1). In ELISAs, this antibody shows 100% cross-reactivity with recombit mouse (rm) IL-23, 30% cross-reactivity with rmIL-12 p70, and no cross-reactivity with recombit human (rh) IL-12 p70 or rhIL-12 p40. Reconstitute at 0.5 mg/mL in sterile PBS.IL-12 is an interleukin produced by dendritic cells, neutrophils, macrophages and human lymphoblastoid cells as a result of antigenic stimulation. IL-12 is a heterodimeric cytokine encoded by IL-12A (p35) and IL-12B (p40). IL-23 is a heterodimeric cytokine that shares a subunit with IL-12 (IL-12B) along with an IL-23A (IL-23p19) subunit. Functionally, IL-12 increases the expression of vascular endothelial adhesion molecule-1 on the endothelium, directs leukocytes towards tumors and facilitates the ischemic-hemorrhagic necrosis of the tumor tissue. In comparison, IL-23 plays an important role in stimulating memory T-cells, and is required for the induction, expansion, maintece and downstream effector functions of Th17 cells, which play a vital role in upregulating neutrophil chemokines and various pro-inflammatory cytokines.
|PBS with 5% trehalose and No Preservative|
|IL12B, Il12p40, interleukin 12B, RP23-388G23.1, Il-12b, Il-12p40, p40, IL-12 p40, IL-23 subunit p40, IL12P40|
|-20° C, Avoid Freeze/Thaw Cycles|
|Sf 21-derived recombit mouse IL-12 p40|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok